2025 has been a cornucopia of massive updates for companies exploring new possibilities in targeting the RAS/MAPK signaling pathway for cancer. I am notably excited about the prospects of companies likeI have my PhD in biochemistry and have worked for years analyzing clinical trials and biotech companies. It is my passion to educate everyone possible on the science behind the businesses that we invest in, and it's my mission to help you do your due diligence and not get burned by the pitfalls of investing i ...